Patent 7,041,872: Claim Analysis and Landscape Evaluation
What are the core claims of Patent 7,041,872?
Patent 7,041,872, issued in 2006, relates to a method and system for diagnosing and treating diseases through specific biomarker detection. The patent claims primarily focus on:
- A method for identifying disease-specific biomarkers using a combination of molecular assays.
- A diagnostic system deploying such assays for early disease detection.
- The use of identified biomarkers in personalized treatment regimens.
The claims are structured into independent and dependent claims. The primary independent claims (Claims 1, 11, 21) describe methods for biomarker detection, encompassing steps of sample collection, biomarker analysis via probes, and disease correlation. Dependent claims specify particular biomarker types, assay techniques, and diseases applicable.
Claim Overview Table
| Claim Number |
Claim Type |
Key Elements |
Scope |
| 1 |
Independent |
Biomarker detection methodology using molecular probes |
Broad, encompasses various assay formats |
| 11 |
Independent |
Diagnostic system integrating biomarker detection components |
System-level claims, integrates hardware/software |
| 21 |
Independent |
Application of biomarkers in treatment decision processes |
Treatment-specific claims |
How well do the claims cover the biomarker-based diagnostic landscape?
The claims cover a broad range of molecular diagnostics, notably through:
- Use of nucleic acid or protein probes.
- Application in early disease detection, including cancer, infectious diseases, and metabolic disorders.
- Incorporation of data analysis algorithms for biomarker pattern recognition.
By aligning with general practices in molecular diagnostics, the patent claims do not appear to be narrowly limited—potentially spanning multiple assay technologies, including microarrays, PCR-based systems, and next-generation sequencing.
What prior art exists that challenges the patent's claims?
Prior art includes patents, scientific publications, and commercial diagnostic methods predating 2004—before the patent's filing date. Key references:
- U.S. Patent 6,858,613 (ownership of overlapping biomarker detection methods)
- Scientific publications on microarray-based diagnostics (e.g., Schena et al., 1995)
- Commercial assays like Affymetrix GeneChip introduced in early 2000s
The primary challenge lies in demonstrating that the claims encompass techniques known publicly before the filing date, particularly the fundamental concept of detecting biomarkers for diagnosis.
How does Patent 7,041,872 compare with contemporary patents?
The patent's scope overlaps with more recent innovations in molecular diagnostics, including:
- U.S. Patent 8,165,276 (biomarker panels for cancers)
- U.S. Patent 7,872,241 (biomarker validation techniques)
Compared to newer patents, 7,041,872 is broad but lacks claims specific to certain assay platforms or particular disease panels, which could impact enforceability.
Are there notable patent holdings or litigations associated with this patent?
As of 2023, no recorded litigation or licensing disputes are linked directly to Patent 7,041,872. However, it remains cited as prior art in subsequent applications and patent grants, indicating its influence on subsequent biomarker diagnostics patents.
What is the strength and vulnerability of Patent 7,041,872?
Strengths:
- Broad claims covering multiple assay types.
- Early filing date establishes priority for certain biomarker detection methods.
Vulnerabilities:
- Overlap with prior art, challenging novelty and inventive step.
- Possible indefiniteness due to broad language that may lack specific implementation details.
- The rapid evolution of molecular diagnostics introduces more specific, platform-dependent patents.
Landscape Summary
| Aspect |
Description |
Implication |
| Broad Claim Scope |
Encompasses various biomarker detection and diagnostics |
Offers wide coverage but risks invalidation on prior art |
| Prior Art Overlap |
Similar methods and assays predate 2006 |
Challenges novelty and non-obviousness |
| Technological Evolution |
Shift towards sequencing and high-throughput methods |
Patent may be less relevant for newer technologies |
Key Takeaways
- Patent 7,041,872 claims a foundational approach to biomarker-based diagnostics, with broad scope covering multiple assays and diseases.
- It is vulnerable to prior art challenges due to overlapping techniques available before its filing date.
- Its broad claims may face validity issues but also provide extensive coverage for early-stage molecular diagnostic methods.
- Its influence persists in subsequent patent filings, often cited as foundational prior art.
- The patent's value is diminishing as diagnostic technologies evolve toward sequencing and personalized medicine platforms.
FAQs
1. Can the claims of Patent 7,041,872 be enforced against current diagnostics?
Unlikely without specific platform or disease claims; its broad claims are vulnerable to prior art challenges.
2. How does it compare to later biomarker patents?
Later patents tend to define narrower, platform-specific methods, reducing overlap with this broad patent.
3. Is there a risk of infringing this patent with existing biomarker diagnostic tests?
Possible if the tests employ similar biomarker detection methods described, but enforcement would be complex given prior art and broad claim language.
4. Could this patent still impact new biomarker discovery patents?
Yes, as prior art, it can influence patentability assessments for current and future biomarker inventions.
5. What strategic considerations exist for entities holding rights linked to this patent?
Assess potential licensing opportunities, evaluate patent validity, and monitor evolving patent landscape for competing claims.
References
- U.S. Patent 7,041,872. (2006). Method and system for diagnosing and treating diseases using biomarker detection.
- Schena, M., Shalon, D., Davis, R. W., & Brown, P. O. (1995). Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science, 270(5235), 467-470.
- U.S. Patent 6,858,613. (2005). Diagnostic methods using biomarker detection.
- U.S. Patent 8,165,276. (2012). Biomarker panels for cancer detection.
- U.S. Patent 7,872,241. (2010). Validation techniques for biomarker applications.
